RBC Capital Mkts raised the price target for the Sage Therapeutics Inc. (NASDAQ:SAGE) stock from “a Sector perform” to “an Outperform”. The rating was released on March 13, 2023, according to finviz. The research report from Loop Capital has initiated the stock to Hold, with a price target set at $41. The stock was initiated by Berenberg, who disclosed in a research note on March 31, 2022, to Hold and set the price objective to $37. In their research brief published November 02, 2021, Guggenheim analysts upgraded the Sage Therapeutics Inc. stock from Neutral to Buy with a price target of $55.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Sage Therapeutics Inc. (NASDAQ:SAGE) dipped -2.04% to close Friday’s market session at $42.75, lower as compared to yesterday’s close. The stock price fluctuated between $42.14 and $43.43 throughout the trading session with the volume trading being 798397 shares, which represented a significant variation when compared to the three months average volume of 494.14K shares. The firm’s stock price fluctuated 8.06% within the last five trades and -5.23% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 1.16% in the last 6 months and 3.44% was added to its value over the previous 3 months. SAGE stock is trading at a margin of 0.54%, -0.97% and 9.19% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
As of the close of trading, SAGE deals in the Healthcare domain. The stock is trading -13.74 percent below its 52-week high and 56.25 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 22.75. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Sage Therapeutics Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $2.78 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 360.99 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 2.03, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.10 percent of Sage Therapeutics Inc. shares are owned by insiders, and 88.70 percent are held by financial institutions. JONAS JEFFREY M, the Director at Sage Therapeutics Inc. (SAGE) has sold 11,643 shares of firm on Feb 10 at a price of $44.61 against the total amount of $0.52 million. In another inside trade, Greene Barry E, President and CEO of Sage Therapeutics Inc. (NASDAQ:SAGE) bought 14,500 shares of the firm on Nov 10 for a total worth of $0.5 million at a price of $34.48. An inside trade which took place on May 05, Director of Sage Therapeutics Inc. Golumbeski George bought 8,000 shares of firm against total price of $0.25 million at the cost of $31.45 per share.